Eli Lilly and Co (NYSE:LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.The company said internal testing detected a previously unidentified impurity formed when the two substances interact.The drugmaker evaluated compounded products marketed in the U.S. that combine tirzepatide with vitamin B12—also referred to as methylcobalamin, hydroxocobalamin, or cyanocobalamin.Laboratory testing revealed significant levels ...

Key Takeaways Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $36.5B in 2025, about 56% of total company revenues.Medicare's BALANCE Model will allow Zepbound and Mounjaro coverage under Part D plans starting in 2027.LLY plans a potential 2Q26 U.S. launch of oral GLP-1 drug orforglipron, if approved, to expand obesity access.Eli Lilly (LLY) , a dominant player in the global obesity market, derives most of its revenues from its blockbuster GLP-1 medicines, Mounjaro for type II diabetes (T2D) and Zepb ...

Market Overview - Major averages are experiencing declines, with the Dow dropping over 400 points as traders assess fluctuating oil prices and a significant inflation report [1] - Markets are trading cautiously due to volatile energy prices and ongoing geopolitical tensions in the Middle East [1] Oil Market Dynamics - Oil prices surged above $100 and briefly approached $120 earlier in the week due to fears of shipping disruptions through the Strait of Hormuz, but have since retreated to below $90 following a coordinated release of emergency reserves [2] - The International Energy Agency has agreed to release approximately 400 million barrels from global strategic stockpiles to stabilize energy markets after a supply shock driven by conflict [2] Geopolitical Tensions - U.S. forces have sunk several Iranian ships, including 16 minelayers, near the Strait of Hormuz, while reports of incidents involving bulk carriers have emerged, highlighting the fragility of global energy supply routes [3] - These developments have contributed to unstable risk sentiment in the market [3] Inflation Data - Recent inflation data indicates that consumer prices rose by 0.3% month-over-month and 2.4% year-over-year, both figures aligning with consensus expectations [4] Company News - Nike (NKE) has been upgraded to Overweight at Barclays due to operational progress [7] - JPMorgan upgraded Oracle (ORCL), citing improved risk/reward following a selloff [7] - Optimum Communications (OPTU) has been downgraded to Market Perform at Raymond James [7] - Yext (YEXT) has been downgraded to Neutral at Roth Capital [7] - Wells Fargo has assigned an Underweight rating to Harley-Davidson (HOG), citing excessive risk [7] - MasterCard (MA) has launched a new Crypto Partner Program, collaborating with over 85 companies in the digital asset and payments sectors [7] - Eli Lilly (LLY) plans to invest $3 billion in China over the next decade [7] - Playboy (PLBY) has appointed Phillip Picardi as chief brand officer and editor in chief [7] - Shell (SHEL) has declared force majeure on liquefied natural gas contracts with some clients in Asia due to the ongoing Qatar LNG shutdown [7] - AMD (AMD) CEO Lisa Su is set to meet with Samsung (SSNLF) Chairman Jay Lee to discuss cooperation on securing supplies of high-bandwidth memory for AI chipsets [7]

Eli Lilly & Co. warned that the active ingredient in its weight-loss blockbuster Zepbound could pose a risk to patients when mixed with vitamin B12, a combination sold by US drug compounders.Lilly tested compounded products and found “significant levels of an impurity” resulting from a chemical reaction between the vitamin and the active ingredient, tirzepatide, it said Thursday. “People receiving tirzepatide-B12 products from compounders, telehealth companies, medspas, or anyone else should be aware that t ...

为什么要在中国如此大手笔投产，答案其实并不复杂。中国已经成为全球减重药竞争最激烈、也最具潜力的市场之一。一方面，肥胖和 代谢类疾病患者基数庞大；另一方面，随着本土药企集体涌入，未来价格竞争和供应效率竞争都会越来越激烈。在这种背景下，谁能更 快建立本土生产和供应体系，谁就更有机会把先发优势转化为市场份额。礼来这次明确提出，要建立口服固体制剂的本土化生产与供应 体系，并采取内部扩建加外部合作的双轮模式，说明它已经不满足于把中国当作销售市场，而是要把这里直接纳入全球制造网络的重要 一环。 整理 | GLP1减重宝典内容团队 全球减重药大战，正在从临床数据竞争，走向产能、供应链和落地速度的全面比拼。3月11日，礼来宣布，未来十年将在中国累计投资 30亿美元，全面扩展本土供应链产能，重点之一就是为其口服小分子GLP-1受体激动剂orforglipron铺设生产能力。这不是一次普通的 扩产决定，而更像是礼来在中国减重药市场打下的一枚重注。公开信息显示，礼来还将与康龙化成展开战略合作，首期预计投入2亿美 元，用于支持后者相关技术能力建设。消息落地后，康龙化成A股和H股双双走强，市场显然迅速捕捉到了这次合作背后的含金量。 这 ...

整理 | GLP1减重宝典内容团队 3月12日，礼来发布公开警告称，公司检测发现，美国市场上一些将替尔泊肽与维生素B12混合配制的复方产品中，出现了由两者化学反 应产生的显著杂质。这一表态迅速引发市场关注，因为它触及的并不只是复方药合不合规的问题，而是更敏感的患者安全问题。 礼来此次警告的核心，并不是反对维生素B12本身，而是强调替尔泊肽与维生素B12在混合后会生成新的杂质，而这种杂质目前几乎没有 清晰的人体数据。礼来称，现阶段并不知道这些杂质在人体内的短期或长期影响，也不清楚它是否会改变替尔泊肽与GLP-1受体、GIP受 体的相互作用，是否会引发新的毒性或免疫反应，以及它在体内的吸收、分布、代谢和排泄路径会不会因此发生变化。换句话说，真正 令人警惕的，不是已经确认出现了什么严重后果，而是风险边界目前仍然不明。 点击关注，追踪最新GLP-1资讯 这也是为什么礼来的措辞如此强硬。对一家原研药企来说，药物一旦离开标准化生产体系，进入各种复方配制、拼装组合和添加未经验 证成分的路径，药物本身就不再是原来的那个药。尤其是替尔泊肽这类结构复杂、商业价值极高、使用人群又在快速扩张的分子，一旦 被大量用于所谓个体化定制产品 ...

Core Insights - Eli Lilly is positioned to benefit from multiple catalysts, particularly in the weight loss sector and the broader trend towards healthier lifestyles [1] - The upcoming launch of Orforglipron, changes in GLP-1 Medicare/Medicaid eligibility, and the introduction of LillyDirect are expected to enhance the company's market presence [1] Group 1: Company Developments - Eli Lilly is set to launch Orforglipron, which is anticipated to contribute significantly to its growth [1] - The company is also focusing on expanding Medicare/Medicaid eligibility for GLP-1 medications, which could increase access and sales [1] - LillyDirect is another initiative aimed at broadening the company's reach in the market [1] Group 2: Market Trends - There is a growing market theme around weight loss and healthier lifestyles, which Eli Lilly is actively engaging with [1] - The company's strategies align with the increasing consumer demand for health-oriented products and solutions [1]

Eli Lilly warned that the active ingredient in Zepbound could pose a risk to patients when mixed with vitamin B12 https://t.co/2LecIXDQuu ...

智通财经APP获悉，高盛发布研报称，康龙化成(03759)与礼来(LLY.US)达成合作协议，支持Orforglipron 在中国的本地供应，礼来预期向康龙化成投资2亿美元，以支持其技术能力建设，并随着项目进展，有 望进一步扩大合作范围。予康龙化成港股"买入"评级，目标价为30.7港元；予康龙化成(300759.SZ)A 股"中性"评级，目标价为38元人民币。 同时，礼来计划在未来十年累计投资30亿美元，与多家本地企业全面扩大其在中国的供应链产能，目标 是为口服固体制剂建立本地化制造及供应体系，特别专注于建设Orforglipron的生产产能。礼来中国已 于2025年底向国家药监局提交Orforglipron用于治疗2型糖尿病及肥胖症的上市申请。该行认为，礼来对 本地资本开支的承诺反映其对中国肥胖症药物市场长期增长潜力的信心。 就对康龙化成的基本面影响而言，对盈利贡献及战略意义的更实质评估将取决于进一步披露，该行预期 管理层将在即将举行的业绩电话会议上提供更多细节，包括合作模式、潜在订单规模，以及 Orforglipron在中国获批后的商业化轨迹。尽管如此，该行预期康龙化成将录得正面市场反应，因该合 作伙伴关 ...

365亿美元 VS 361亿美元。 2025年全球"药王"终极对决，落下帷幕。礼来替尔泊肽以4亿美元的微弱优势，硬生生把诺和诺德司美格鲁肽拽下王座。两款GLP-1减肥 药包揽冠亚军，蝉联两年销冠的默沙东K药，直接被挤出头部梯队。 谁能想到，这场千亿赛道的狂欢，起点竟是马斯克 2021年的一条社交动态。一张带货照，把司美格鲁肽从小众降糖药，捧成风靡全球的减肥神药，诺和诺德躺着 吃了三年先发红利。短短五年，王座易主，行业彻底洗牌。 就在所有人笃定，减肥药战场注定是礼来、诺和诺德双雄垄断，旁人连喝汤的份都没有时， 2026年早春，一个"掉队者"杀疯了—— 辉瑞 。 自研管线全线崩盘， GLP-1赛道彻底缺席，这个177岁的老牌巨头，凭什么敢硬闯双雄壁垒？放着全球市场不深耕，偏偏把首款减肥药的命运，全盘押注中国？ 01 双雄崩盘，辉瑞突袭： GLP-1格局彻底改写 2026年2月23日，诺和诺德遭遇股灾。股价暴跌超15%，创下近五年最大跌幅，市值单日蒸发数百亿美元，华尔街一片哗然。 导火索很扎心：旗下下一代减肥神药 CagriSema，84周减重23.0%，直接被礼来替尔泊肽25.5%的成绩碾压，连"不劣于"的底线都 ...